Nasdaq
$16.64▼ 0.12%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $1.01BShares out 61.0M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
5- 8.13Regular26.08.14 01:42SCHEDULE 13G/AOwnership#●●●#●●●
Janux Therapeutics, Inc.
Janus Henderson Group Ltd. has filed a Power of Attorney appointing Kristin Mariani and Caroline Barotti as attorneys-in-fact to handle SEC reporting requirements for the company and its affiliates. This filing formalizes the administrative process for managing ownership disclosures across 13 asset management entities, including Janus Henderson Investors US LLC.…more
$16.64-0.12%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 8.6After-hours26.08.07 05:1810-QEarnings
Janux Therapeutics, Inc.
재누스 테라퓨틱스(Janux Therapeutics)의 2026년 6월 30일 기준 재무제표에 따르면, 총 자산은 10억 765만 달러로 2025년 말 대비 소폭 증가했습니다. 당기 중 유동부채는 6,015만 달러로 증가했으며, 2026년 8월 4일 기준 발행 주식 수는 6,113만 6,773주입니다.…more
$16.64-0.12%vs prev closeView filingShare - 8.6After-hours26.08.07 05:088-KKey event
Janux Therapeutics, Inc.
재너스 테라퓨틱스는 2026년 2분기 실적 발표를 통해 2,197만 달러의 순손실과 9억 7,090만 달러의 현금 및 단기 투자 자산을 보유했다고 보고했다. 현재 JANX007과 JANX014 등 주요 임상 파이프라인의 환자 등록이 진행 중이며, JANX013의 임상 개시는 2026년 하반기로 예정되어 있다.…more
$16.64-0.12%vs prev closeView filingShare
4 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 9.14Pre-market26.09.14 21:07#●●●#●●●#●●●
Janux Therapeutics Doses First Patient in Phase 1 Trial for JANX013
Janux Therapeutics has initiated a Phase 1 clinical trial for its prostate cancer candidate, JANX013, by dosing the first patient. The study aims to evaluate the safety and efficacy of the drug in combination with JANX007 to enhance anti-tumor immune responses.…more
$16.64-0.12%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga